Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ATS Corp T.ATS

Alternate Symbol(s):  ATS

ATS Corporation is a Canada-based automation solutions provider. The Company uses its knowledge base and global capabilities in custom automation, repeat automation, automation products and value-added services, including pre-automation and after-sales services, to address the sophisticated manufacturing automation systems and service needs of multinational customers in markets, such as life... see more

TSX:ATS - Post Discussion

ATS Corp > RBC
View:
Post by retiredcf on Sep 22, 2023 9:10am

RBC

September 22, 2023

ATS Corporation
Announces acquisition of Avidity Science for US$195MM

TSX: ATS | CAD 57.57 | Outperform | Price Target CAD 69.00

Sentiment: Positive

What happened – ATS Corporation ("ATS") announced it has agreed to acquire Avidity Science, LLC ("Avidity"), a designer/ manufacturer of Life Sciences automated water purification solutions, for US$195 million (~C$265 million). This represents 11.2x Avidity's 2023E Adjusted EBITDA (10.3x including synergies) and compares to ATS' current trading multiple of 12.5x F2025E Adjusted EBITDA. For background, Avidity generated US$81.9MM of revenue (40% recurring) and a 20.4% Adjusted EBITDA margin (implying ~US$16.7MM of Adjusted EBITDA) in calendar year 2022. In CAD, this implies ~$110MM of revenue and ~$22.5MM of EBITDA (~4% and ~5% of our F2024 revenue and Adjusted EBITDA forecasts, respectively).

Synergies and pro-forma leverage – ATS expects to realize US$1.5 million of synergies by year 3 and US$2.6 million by year 5 post-close. The company will fund the acquisition with cash and by drawing on its revolving credit facility, and projects pro-forma leverage of ~2.5x. The transaction is expected to close in the fourth calendar quarter of 2023.

Conference call at 8:30am ET – On the 8:30am call today, we will look for additional colour on: 1) how the Avidity business fits within ATS' Life Sciences offering; 2) Avidity's recent revenue growth/margin trajectory and management's expectations for the coming years; and, 3) integration plans given Avidity has a global customer base.

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities